Surgery Partners stock hits 52-week low at $15.09

Surgery Partners (SGRY) hit a 52‑week low of $15.09 after shares tumbled roughly 33% year‑over‑year and 36% over six months as investor confidence waned; the company reported Q3 revenue of $822m and adjusted EBITDA of $136m in line with estimates but trimmed its Q4 guidance, cutting full‑year 2025 adjusted EBITDA guidance by about 4% at the midpoint. The guidance revision, cited operational pressure and an unfavorable payer mix that reduced near‑term earnings visibility, prompted analysts to lower targets (Mizuho $22, UBS $29, Benchmark $30, RBC $31) despite retained Outperform/Buy ratings, while InvestingPro flags the stock as oversold with a $20–$33 target band. Management moves include naming Justin Oppenheimer as COO and national group president effective Jan. 1, 2026; the market takeaway is continued downside risk absent clear operational improvements or restored earnings visibility.

Analysis

Surgery Partners (SGRY) closed at a 52-week low of $15.09 after a 33.42% year‑over‑year drop and a 36.17% decline over the past six months, reflecting pronounced investor confidence erosion in the company and broader healthcare sector headwinds. The company reported third‑quarter revenue of $822 million and adjusted EBITDA of $136 million, which matched consensus, but the market reaction centers on the company’s downward revision to fourth‑quarter guidance that reduces full‑year 2025 adjusted EBITDA guidance by about 4% at the midpoint.

Analyst responses trimmed price targets—Mizuho to $22 (Outperform), UBS to $29 (Buy), Benchmark to $30, and RBC to $31—while InvestingPro flags the shares as oversold with a $20–$33 target band, indicating divergent views between near‑term risk and medium‑term upside scenarios. Concerns cited in reports include a worsening payer mix and reduced earnings visibility, which justify the share‑price pressure despite consensus‑matching Q3 results.

Management is introducing Justin Oppenheimer as COO and national group president effective January 1, 2026, a move aimed at operational improvement but unlikely to materially change near‑term earnings visibility. Primary catalysts to monitor are updated Q4 guidance, payer‑mix and margin trends, and whether subsequent analyst revisions converge toward recovery, as absence of clear operational fixes leaves downside risk intact.

Key Decisions for Investors

• Do not initiate large new long positions until the company provides clearer Q4 guidance or demonstrable stabilization in payer‑mix and margins, given the 4% cut to 2025 adjusted EBITDA guidance and the 52‑week low at $15.09
• If seeking exposure, use small, hedged positions or tranches and target re‑assessment only after one or two quarters of visible operational improvement or upward revisions from analysts in the $20–$33 band
• Monitor three near‑term catalysts—updated Q4/full‑year commentary, payer‑mix trends and margin progression, and tangible operational progress under the incoming COO—and adjust position size promptly if these data points fail to improve